Engene Therapeutics Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
(Values in U.S. thousands)
| 10-2025 | 10-2024 | 10-2023 | 12-2022 | 10-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -117,302 | -55,142 | -99,917 | 31 | -24,462 |
| Depreciation Amortization | -2,558 | 91 | 175 | N/A | 238 |
| Accounts payable and accrued liabilities | 4,942 | 474 | 373 | N/A | -197 |
| Other Working Capital | 9,740 | 95 | -517 | 1,076 | 2,174 |
| Other Operating Activity | 5,939 | 6,201 | 75,143 | -1,862 | 4,655 |
| Operating Cash Flow | $-99,239 | $-48,281 | $-24,743 | $-755 | $-17,592 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -23,653 | -125,028 | N/A | N/A | N/A |
| PPE Investments | -1,485 | -925 | -318 | N/A | -153 |
| Investing Cash Flow | $-25,138 | $-125,953 | $-318 | $N/A | $-153 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 38,000 | N/A | 18,400 |
| Debt Issued | N/A | 22,500 | N/A | N/A | 11,000 |
| Debt Repayment | -699 | -9,445 | -1,555 | N/A | -1,010 |
| Common Stock Issued | 2,223 | 266,245 | 56,936 | N/A | 12 |
| Other Financing Activity | 0 | -13,584 | -7,234 | 0 | -435 |
| Financing Cash Flow | $1,524 | $265,716 | $86,147 | $N/A | $27,967 |
| Exchange Rate Effect | 1 | 1 | 1 | N/A | -805 |
| Beginning Cash Position | 173,004 | 81,521 | 20,434 | 1,069 | 11,017 |
| End Cash Position | 50,152 | 173,004 | 81,521 | 314 | 20,434 |
| Net Cash Flow | $-122,852 | $91,483 | $61,087 | $-755 | $9,417 |
| Free Cash Flow | |||||
| Operating Cash Flow | -99,239 | -48,281 | -24,743 | -755 | -17,592 |
| Capital Expenditure | -1,485 | -925 | -318 | N/A | -153 |
| Free Cash Flow | -100,724 | -49,206 | -25,061 | -755 | -17,745 |